Petros Pharmaceuticals, Inc. Embedded Derivative Liability, Measurement Input
Petros Pharmaceuticals, Inc. (PTPI) had Embedded Derivative Liability, Measurement Input of 12.50% as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:EmbeddedDerivativeLiabilityMeasurementInput · last filed 2024-11-13
- 2024-09-30: Embedded Derivative Liability, Measurement Input 12.50%.
- 2024-06-30: Embedded Derivative Liability, Measurement Input 20.50%.
- 2024-03-31: Embedded Derivative Liability, Measurement Input 6.40%.
- 2023-12-31: Embedded Derivative Liability, Measurement Input 14.00%.
| Period end | Embedded Derivative Liability, Measurement Input |
|---|---|
| 2024-09-30 | 12.50% 10-Q · filed 2024-11-13 |
| 2024-06-30 | 20.50% 10-Q · filed 2024-08-14 |
| 2024-03-31 | 6.40% 10-Q · filed 2024-05-15 |
| 2023-12-31 | 14.00% 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |